Intellia rises after US FDA lifts hold on heart disease gene therapy trial

INTELLIA THERAPEUTICS

02/03/2026 15:16

Updates

** Shares of gene therapy developer Intellia Therapeutics NTLA.O rise 3.1% to $14.21

** Co says the U.S. Food and Drug Administration has removed a clinical hold on the late-stage trial of its experimental gene therapy for a heart disease

** Last year, the company said the FDA paused its two main late-stage trials for the gene-editing treatment, nexiguran ziclumeran, after a patient died from severe liver complications

** In January, the FDA removed its clinical hold on one of the trials, MAGNITUDE-2, after the company took mitigation measures such as enhanced monitoring of liver laboratory tests and the exclusion of patients with certain liver abnormalities

** "Beyond these changes, it's worth saying that getting off this hold was quite quick, and probably comes with minimal disruption to the clinical timeline," Evercore ISI says

** The therapy is being tested in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), a serious and worsening heart disease in which an abnormal protein builds up in the heart, making it stiff and less able to pump blood properly

** Including session's moves, NTLA rose 56.4% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))